A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma

摘要: Background. Metastatic renal cell carcinoma (RCC) is largely chemoresistant. The efficacy of cycle specific chemotherapeutic agents, particularly those with short half-lives, may be enhanced by the use constant rate infusion schedules. Infusional floxuridine has been demonstrated to have a response approximately 20%. vinblastine not tested extensively in patients metastatic RCC. sequential these agents was designed increase and limit toxicity. Methods. Fifteen RCC were treated floxuridine, 0.075 mg/kg/day for 14 days, followed vinblastine, 0.7 mg/m2/day days. repeated every 28 days doses incrementally increased until maximum tolerated dose (MTD) each patient reached. Results. Four had partial responses (27%), which maintained 3, 9, 16 19+ months, whereas five stable disease 3–15 months. Median survival from initiation therapy 379 Three four occurred nonpulmonary locations, all who prior nephrectomy. MTD 0.1 mg/m2/day. Toxic reaction limited diarrhea, principle dose-limiting toxic neutropenia. Catheter-related complications also observed. Conclusions. Alternating active treatment Whether this regimen superior infusional undetermined. Although toxicity associated manageable, it appears more severe than that reported alone. Cancer 1994; 73:2803–7.